BridgeBio Pharma to Participate in Multiple Investor Conferences in September
News provided byBridgeBio Pharma, Inc · 1 min read
PALO ALTO, Calif., Sept. 01, 2026 /CourierPR/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on developing medicines for genetic conditions, has announced its management team will participate in several upcoming investor conferences, providing insights into its ongoing research and development efforts.
On Wednesday, September 9, members of BridgeBio’s management will participate in a fireside chat at the 21st Annual Wells Fargo Healthcare Conference in Boston, Massachusetts. The event is scheduled to begin at 1:30 pm Eastern Daylight Time (EDT).
Following this, on Thursday, September 10, BridgeBio representatives will join the 2026 Cantor Global Healthcare Conference in New York, New York, where the session is set for 9:10 am EDT.
BridgeBio’s presence at the Morgan Stanley 24th Annual Global Healthcare Conference in New York is set for Tuesday, September 15, with a session at 10:00 am EDT.
The company will also participate in the Bernstein Insights Healthcare Leaders and Disruptors 2026 conference on Wednesday, September 23, at 9:40 am EDT, also in New York.
Investors can access the live webcast of these presentations by visiting the “Events and Presentations” page within the Investors section of BridgeBio’s website. A replay will be available for 90 days following each event.
BridgeBio Pharma was founded with the goal of developing transformative medicines for genetic conditions, addressing the significant gap in treatment options for millions of patients worldwide. The company’s decentralized, hub-and-spoke model is designed to accelerate the development of innovative treatments, ensuring precision and scalability in its approach.
To learn more about BridgeBio’s mission and projects, visit the company’s website at bridgebio.com. Follow BridgeBio on LinkedIn, X (formerly Twitter), Facebook, Instagram, YouTube, and TikTok for the latest updates.
BridgeBio’s active participation in these investor conferences underscores its commitment to engaging with the financial community and providing transparent updates on its progress.